Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) was the target of some unusual options trading activity on Thursday. Stock investors bought 72,397 call options on the company. This represents an ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the ...

Many HIV/AIDS researchers are hopeful that the drug, developed by American biopharmaceutical company Gilead Sciences, will powerfully drive down global infection rates when used as pre-exposure ...

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from ...

Cancer drug company Gritstone Bio Inc. will sell off its pieces to three bidders through U.S. Bankruptcy Court, aiming for a ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.

A review found half of the drugs studied had price increases based on new evidence of benefits, while the other half did not.